Search Results
You are looking at 1 - 2 of 2 items for
- Author or Editor: Yeon Chae x
- Refine by Access: All Content x
Abstract
OBJECTIVE
To evaluate the relationships between the severity of myxomatous mitral valve disease (MMVD) and pulmonary hypertension (PH) and serum angiopoietin (Ang)-1 and Ang-2 concentrations in dogs with MMVD.
ANIMALS
74 dogs (control, n = 12; MMVD, n = 62) were included.
METHODS
Serum Ang-1 and Ang-2 concentrations were estimated using the canine-specific ELISA kit. The concentrations were compared between dogs with MMVD and healthy dogs, and they were analyzed according to the severity of MMVD and PH.
RESULTS
The median serum Ang-1 concentration did not differ among the study groups. The median serum Ang-2 concentration was higher in dogs with stage B2 MMVD (P = .041) and acute congestive heart failure (P = .002) than in control dogs. In addition, the median serum Ang-2 concentration was higher in MMVD dogs with PH than in those without PH (P = .031). Serum Ang-2 concentration was correlated with vertebral heart score (rs = 0.36, P = .004) and vertebral left atrial score (r = 0.50, P < .001) in dogs with MMVD, and correlated with vertebral heart score (r = 0.63, P = .01), maximum E wave amplitude of the diastolic transmitral flow (rs = 0.61, P = .018), ejection fraction (rs = –0.77, P < .001) and fractional shortening (rs = –0.56, P = .032) in dogs with acute congestive heart failure.
CLINICAL RELEVANCE
Circulating Ang-2 levels increase in dogs with the severity of MMVD and the presence of PH.
Abstract
OBJECTIVE
To investigate the neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR) in dogs with myxomatous mitral valve disease (MMVD).
ANIMALS
106 dogs with MMVD and 22 healthy dogs were included in the study.
PROCEDURES
CBC data were obtained retrospectively, and NLR, MLR, and PLR were compared between dogs with MMVD and healthy dogs. The ratios were also analyzed according to MMVD severity.
RESULTS
NLR and MLR were significantly higher in dogs with MMVD C and D (NLR of 4.99 [3.69–7.27]; MLR of 0.56 [0.36–0.74]) than in healthy dogs (NLR: 3.05 [1.82–3.37], P < .001; MLR: 0.21 [0.14–0.32], P < .001), MMVD stage B1 (NLR: 3.15 [2.15–3.86], P < .001; MLR: 0.26 [0.20–0.36], P < .001), and MMVD stage B2 dogs (NLR: 3.22 [2.45–3.85], P < .001; MLR: 0.30 [0.19–0.37], P < .001). The area under the receiver operating characteristic curves of the NLR and MLR to distinguish dogs with MMVD C and D from those with MMVD B were 0.84 and 0.89, respectively. The optimal cutoff value for NLR was 4.296 (sensitivity, 68%; specificity, 83.95%), and the MLR value was 0.322 (sensitivity, 96%; specificity, 66.67%). NLR and MLR were significantly decreased after treatment in dogs with congestive heart failure (CHF).
CLINICAL RELEVANCE
NLR and MLR can be used as adjunctive indicators of CHF in dogs.